July 13, 2009 -
Potential to visualize beta-Amyloid plaques in Patients with Alzheimer’s disease demonstrated / Florbetaben may innovate the diagnostic capabilities –
Bayer Schering Pharma AG, Germany, has presented positive data on a global Phase II study with the novel positron emission tomography (PET) tracer florbetaben (BAY 94-9172) at the
International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria. This study showed that patients with a clinical diagnosis of Alzheimer´s disease could be differentiated from age-matched healthy volunteers (HVs) on the basis of florbetaben uptake pattern in the brain.
Until now, the clinical diagnosis of Alzheimer´s disease (AD) with current methods such as cognitive tests is still limited. Currently, a definite diagnosis of Alzheimer´s disease is only possible post mortem. The results of this study showed PET images with a high specificity of over 90 percent: More than 90 percent of the HVs had a negative florbetaben scan (i.e. no tracer uptake) in the relevant brain regions. The results also show a sensitivity of approximately 80 percent indicated by the clinical diagnosis, meaning that about 80 percent of the clinically suspected Alzheimer patients had positive florbetaben scans indicating the presence of beta-Amyloid plaques. This is in line with the results of studies comparing the clinical diagnosis with the definite post mortem histopathological diagnosis...
...
...Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life...
Bayer Schering Pharma's Press Release -
June 4, 2010 (New York, NY) - Paves the way for a new paradigm in the early diagnosis and management of Alzheimer’s disease – WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer’s disease (AD) and related disorders are currently being diagnosed and treated.
Through this collaboration, the two companies will develop specific markers that will aid in the diagnostics and management of Tau-protein related AD using brain-imaging technology. The diagnostics they are jointly aiming to develop will have application in disease treatment and potentially disease prevention... [PDF] TauRx Pharmaceuticals' Press Release -
